| | References | Number of participants | Number of males/females | Diagnosis standard | Age (years) | Disease duration | NYHA classification | Intervention | Control | Course | Outcome measures |
| | Duhai et al. 2012 [11] | T 32/C 30 | T 22/10
C 18/12 | Internal medicine | T
C | T m
C m | III-IV | Baihuasheshecao, Shichangpu, Danshen, Dilong, Taizishen, Chishao, Huangqi, Gegen, Danggui, Danpi, Sharen, Daqingye, Quanxie, Caodoukou + CMT | CMT + Qishenyiqi dripping pills | 2 M | BNP, 6MWT |
| | Zhaozhan 2014 [12] | T 45/C 45 | T 35/10
C 36/9 | Internal medicine | T
C | T y
C y | II–IV | Baihuasheshecao, Shichangpu, Danshen, Dilong, Taizishen, Chishao, Gegen, Huangqi, Quanxie, Danggui, Danpi, Sharen, Daqingye, Caodoukou + CMT | CMT | 2 M | BNP, LVEF |
| | Wenyu and Yuhong 2009 [13] | T 45/C 40 | T 29/16
C 25/15 | WHO/ISFC | T 16–70,
M = 41
C 17–71,
M = 40 | Unclear | II–IV | Fuzi, Baizhu, Fuling, Baishao, Danggui, Taoren, Guizhi, Huangqi, Renshen, Zhigancao, Honghua, Shengjiang, Rougui + CMT | CMT | 6 W | LVEF, SV |
| | Qing and Daoqing 2013 [14] | T 26/C 26 | T 12/14
C 11/15 | Chinese meeting summary | T
C | T y
C y | II–IV | Huangqi, Dangshen, Danshen, Yiyiren, Fuzi, Zhigancao, Guizhi, Chuanxiong, Fuling, Zelan, Zexie, Tinglizi, Jiangxiang + CMT | CMT | 2 M | LVEF, LVEDD |
| | Yi 2013 [15] | T 70/C 65 | T + C 92/43 | Practical Department of Internal Medicine | T
C | Unclear | III-IV | Fuling, Zhuling, Zexie, Tinglizi, Baishao, Baizhu, Fuzi, Shuizhi, Huangqi, Dangshen, Guizhi + CMT | CMT | 2 W | LVEF, overall efficacy |
| | Min et al. 2008 [16] | T 116/C 59 | T 61/55
C 33/26 | WHO/ISFC | T 6–80,
M = 43.1
C 8–75,
M = 39 | T 3 M–10 Y,
M = 4.9 Y
C 6 M–9 Y,
M = 4.6 Y | II–IV | Huangqi, Sanqi, Danshen, Shengdihuang, Huanglian, Lianqiao, Guizhi, Fuling, Danpi + CMT | CMT | 300 D | LVEF, SV, overall efficacy |
| | Xinyu et al. 2001 [17] | T 16/C 12 | T 9/7
C 7/5 | Chinese meeting summary | T 22–60 Y
C 28–62 Y | Unclear | II–IV | Huangqi, Fuzi, Guizhi, Fangji, Dangshen, Fuling, Danshen, Yuzhu, Chishao, Buguzhi, Baizhu + CMT | CMT | 2 M | LVEF |
| | Hongya and Yanjie 2008 [18] | T 35/C 30 | T 21/14
C 19/11 | WHO/ISFC | T 30–61 Y,
M = 41
C 28–63 Y,
M = 42 | Unclear | II–IV | Renshen, Guizhi, Maidong, Shengdihuang, Ejiao, Huomaren, Muxiang, Yuanzhi, Wuweizi + CMT | CMT | 12 M | LVEF, overall efficacy |
| | Lili and Hui 2005 [19] | T 30/C 30 | T 18/12
C 16/14 | Chinese meeting summary | T 16–60 Y,
M = 38.2
C 18–58 Y,
M = 37.5 | T 1.5–10 Y,
M = 4.5
C 1–11 Y,
M = 4.2 | II-III | Huangqi, Taoren, Renshen, Tinglizi, Fuling, Danshen, Wujiapi, Guizhi, Fuzi, Honghua +CMT | CMT | 1 M | LVEF, SV, LVEDD, overall efficacy LVEDD |
| | Hui et al. 2004 [20] | T 32/C 21 | T 20/12
C 13/8 | WHO/ISFC | T
C | T M
C M | II–IV | Huangqi, Renshen, Maidong, Wuweizi, Guizhi, Baizhu, Fuling, Wujiapi, Zelan, Danshen, Gegen, Yuzhu, Xianlingpi, Zhigancao + CMT | CMT | 3 M | LVEF, SV |
| | Rongqi 2009 [21] | T 34/C 30 | T 24/10
C 22/8 | Chinese meeting summary | T 30–63 Y,
M = 40.2
C 35–62 Y,
M = 39.5 | T 6 M–7 Y
C 5 M–8 Y | II–IV | Renshen, Shuizhi, Zhigancao, Guizhi, Maidong, Shengdihuang, Gansong, Chuanxiong, Tinglizi, Zexie + CMT | CMT | 6 M | LVEF, LVEDD, overall efficacy |
| | Xi and Jianhua 2006 [22] | T 39/C 39 | T 29/10
C 28/11 | WHO/ISFC | T M = 43.6
C M = 46.8 | T M = 632 D
C M = 647 D | II–IV | Huangqi, Renshen, Danshen, Fuzi, Maidong, Tanxiang, Wuweizi, Zelan Danggui + CMT | CMT | 3 M | LVEF, LVEDD, overall efficacy |
| | Renping et al. 2004 [23] | T 45/C 44 | T 29/16
C 26/18 | WHO/ISFC | T 7–72,
M = 40.2
C 10–69,
M = 38.1 | T 0.5–10,
M = 4.8 Y
C 0.8–9,
M = 4.5 Y | III-IV | Huangqi, Dangshen, Guizhi, Chuanxiong, Danshen, Sanqi, Huanglian, Lianqiao + CMT | CMT | 1 Y | 6MWT, LVEF, SV, overall efficacy |
| | Shaohan et al. 2005 [24] | T 46/C 40 | T 29/17
C 24/16 | WHO/ISFC | T 2–70,
M = 39
C 2–69,
M = 41 | Unclear | II–IV | Huangqi, Dangshen, Baizhu, Zhigancao, Danggui, Shengma, Chaihu, Fuling, Danshen, Suanzaoren, Juhong, Zhiqiao, Zhuru, Banxia + CMT | CMT | 8 W | LVEF, overall efficacy |
| | Yongxuan and Bende 1997 [25] | T 60/C 40 | T 36/24
C 26/14 | Practical Department of Internal Medicine | Unclear | Unclear | II–IV | Taizishen, Maidong, Wuweizi, Fuling, Zhuling, Baizhu, Guizhi, Zexie, Suanzaoren, Yuanzhi, Longgu, Muli, Zhigancao + CMT | CMT | 2 W | LVEF, SV, overall efficacy |
| | Xuebin et al. 1995 [26] | T 21/C 18 | T 19/2
C 15/3 | WHO/ISFC | T 16–67,
M = 42
C 24–60,
M = 47 | T 1–9 Y,
M = 4.3
C 10 M–7 Y,
M = 3.9 | II–IV | Huangqi, Danshen, Fuzi, Chuanxiong, Xianlingpi + CMT | CMT | 2 W | LVEF, SV, LVEDD, overall efficacy |
| | Wanqiang et al. 1999 [27] | T 40/C 40 | T 26/14
C 24/16 | WHO/ISFC | T 18–62,
M = 39.8
C 17–66,
M = 40.3 | Unclear | II–IV | Renshen, Huangqi, Danggui, Chuanxiong, Baizhu, Maidong, Wuweizi, Suanzaoren, Boziren, Yuanzhi, Zhiqiao, Fuling, Fushen, Banxia, Zhigancao + CMT | CMT | 4 W | LVEF, LVEDD, overall efficacy |
| | Huiwen et al. 2013 [28] | T 30/C 30 | T + C 42/18 | Internal Medicine | | M | II–IV | Changpu, Danshen, Baihuasheshecao, Taizishen, Chishao, Huangqi, Gegen, Danggui, Danpi, Daqingye, Quanxie, Dilong, Sharen, Caodoukou + CMT | CMT | 2 M | BNP, 6MWT, LVEF, LVEDD, overall efficacy |
| | Wuyi 2012 [29] | T 23/C 20 | T 13/10
C 11/9 | Chinese meeting summary | T 46–77,
M = 48.6
C 40–78,
M = 46.7 | T 1.5–10 Y,
M = 3.2
C 1-9 Y,
M = 3.8 | II–IV | Huangqi, Fuling, Danggui, Renshen, Maidong, Wuweizi, Fuzi, Rougui, Guizhi, Baizhu, Zexie, Tinglizi, Danshen + CMT | CMT | 90 D | 6MWT,LVEF, LVEDD, overall efficacy |
| | Qunyan 2012 [30] | T 32/C 30 | T 20/12
C 19/11 | WHO/ISFC | T 41–78,
M = 47.8
C 40–73,
M = 45.6 | T 1–11 Y,
M = 3.1
C 1–12,
M = 3.2 | II–IV | Gancao, Renshen, Shengjiang, Guizhi, Shengdihuang, Shuizhi, Tinglizi, Ejiao, Maidong, Huomaren, Dazao + CMT | CMT | 3 M | 6MWT, LVEF, LVEDD, overall efficacy |
| | Jinliang et al. 2011 [31] | T 30/C 30 | T 27/3
C 26/4 | Chinese meeting summary | T
C | Unclear | II–IV | Huangqi, Danggui, Renshen, Maidong, Wuweizi, Guizhi, Fuling, Zexie, Yimucao, Tinnglizi, Baizhu, Chenpi, Dazao, Shenggancao + CMT | CMT | 90 D | 6MWT, LVEF, LVEDD, overall efficacy |
|
|
